Analysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) PT at $4.86

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.8571.

A number of brokerages recently weighed in on MRVI. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th.

Maravai LifeSciences Stock Performance

MRVI opened at $3.08 on Thursday. The firm has a market cap of $787.59 million, a PE ratio of -3.42 and a beta of 0.38. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The business has a fifty day simple moving average of $3.48 and a 200-day simple moving average of $3.28. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%.The company had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. As a group, equities analysts predict that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently made changes to their positions in the company. Sprott Inc. acquired a new position in Maravai LifeSciences in the 3rd quarter worth approximately $29,000. Quantessence Capital LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter valued at $31,000. Abel Hall LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter valued at $33,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Maravai LifeSciences in the third quarter valued at $33,000. Finally, Virtu Financial LLC purchased a new stake in shares of Maravai LifeSciences in the fourth quarter valued at $34,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.